SCHEMBL20595774

SCHEMBL20595774

COC(=O)CNCc1ncccc1-c1ccc(OC)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDCD1 Q15116 2/20 0.42
▸ CD274 Q9NZQ7 2/20 0.42
▸ MAPT P10636 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ BLM P54132 1/20 0.39
▸ P2RX7 Q99572 1/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ CLK4 Q9HAZ1 2/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ MAPK8 P45983 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ DGAT2 Q96PD7 1/20 0.37
▸ GLA P06280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595767 0.77 HSP90AA1 (0.41) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL20595768 0.77 CDC7 (0.38) MAPTJAK2TYK2CDC7CCNT1
SCHEMBL20595575 0.71 HSP90AA1 (0.44) KMT2AMEN1CYP1A2CYP3A4CYP2D6
SCHEMBL21522559 0.69 PDCD1 (0.44) PDCD1CD274SMN1; SMN2P2RX7KMT2A
SCHEMBL1269158 0.68 APLNR (0.71) KMT2AMEN1TSHRALDH1A1HPGD
SCHEMBL12325069 0.67 HSP90AA1 (0.56) MAPTKMT2AMEN1CYP1A2CYP3A4
SCHEMBL29464785 0.66 MAOA (0.48) MAPTKMT2AMEN1CYP3A4LMNA
SCHEMBL13044624 0.65 SMN1; SMN2 (0.43) MAPTSMN1; SMN2KMT2AMEN1CYP1A2
SCHEMBL473984 0.65 ALDH1A1 (0.53) MAPTSMN1; SMN2KMT2AMEN1LMNA
SCHEMBL16107035 0.65 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMEN1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 PDCD1 3893/4885CD274 4626/4885MAPT 3686/4885
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR PDCD1 4161/4885CD274 4715/4885MAPT 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback